INHIBITORY AGENT FOR HUMAN ACQUIRED IMMUNODEFICIENCY SYNDROME VIRUS INFECTION

PURPOSE:To provide the subject inhibitor containing a specific spergualin-related compound as an active ingredient, low in toxicity, and excellent in safety, antitumor activity and immune-enhancing activity. CONSTITUTION:The objective inhibitor contains a spergualin-related compound (salt) of formula I [Gu is guanidino; X0 is (CH2)1-5, (substituted)phenylene; (a) is 3-5; X1 (CH2)0-2-CH(CH00)(CH2)0-2 (R00 is H, OH, OCH3, etc); X2 is NH(CH2)4 NH (CH2)3NH-R02 (R02 is H, the OH-removed residue of the carboxyl group of an amino acid or peptide)] or a spergualin-related compound (salt) of formula II [X is (CH2)1-5, C6H4; (r) is 3-5; R6 is the residue produced by removing one H atom from the alpha-amino group and a hydroxyl group from the alpha-carboxyl group of an amino acid, etc.]. The compound is orally administered at a dose of preferably 5-500mg/kg.day.